CLCN3 and breast cancer: Its ability to target ClC-3 channels and MMP-2 in glioblastoma and breast cancer positions it as a promising candidate for further preclinical and clinical evaluation, particularly in the development of tumor-specific diagnostic and therapeutic agents.